Repligen Corporation (NASDAQ:RGEN) Receives $173.85 Average Price Target from Brokerages

Repligen Corporation (NASDAQ:RGEN) has received an average recommendation of “Moderate Buy” from the fifteen analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $173.8462.

Several research firms recently weighed in on RGEN. HSBC began coverage on shares of Repligen in a research note on Wednesday, October 1st. They set a “buy” rating and a $150.00 price objective on the stock. Jefferies Financial Group set a $160.00 price target on Repligen and gave the stock a “hold” rating in a research report on Tuesday, October 28th. Evercore ISI boosted their price objective on Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a research note on Wednesday, October 1st. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research report on Tuesday, September 2nd.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Twin Tree Management LP acquired a new stake in shares of Repligen in the first quarter valued at approximately $29,000. Hantz Financial Services Inc. grew its holdings in Repligen by 2,663.6% in the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after buying an additional 293 shares in the last quarter. Signaturefd LLC increased its position in Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 128 shares during the period. CWM LLC raised its stake in Repligen by 67.2% during the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 135 shares in the last quarter. Finally, Center for Financial Planning Inc. raised its stake in Repligen by 34.2% during the 2nd quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 126 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Performance

Shares of RGEN opened at $158.01 on Friday. The stock has a market capitalization of $8.89 billion, a PE ratio of 7,904.45, a price-to-earnings-growth ratio of 3.32 and a beta of 1.14. The business’s fifty day moving average price is $139.88 and its 200 day moving average price is $129.57. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. Repligen has a 12-month low of $102.96 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The company had revenue of $188.80 million for the quarter, compared to analysts’ expectations of $181.23 million. During the same period in the prior year, the company earned $0.43 earnings per share. The firm’s revenue was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Equities research analysts forecast that Repligen will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.